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Abstract: We conducted a two-sample Mendelian randomization study to explore the associations
of iron status with overall cancer and 22 site-specific cancers. Single-nucleotide polymorphisms
for iron status were obtained from a genome-wide association study of 48,972 European-descent
individuals. Summary-level data for breast and other cancers were obtained from the Breast Cancer
Association Consortium and UK Biobank. Genetically predicted iron status was positively associated
with liver cancer and inversely associated with brain cancer but not associated with overall cancer or
the other 20 studied cancer sites at p < 0.05. The odds ratios of liver cancer were 2.45 (95% CI, 0.81,
7.45; p = 0.11), 2.11 (1.16, 3.83; p = 0.02), 10.89 (2.44, 48.59; p = 0.002) and 0.30 (0.17, 0.53; p = 2 × 10−5)
for one standard deviation increment of serum iron, transferrin saturation, ferritin and transferrin
levels, respectively. For brain cancer, the corresponding odds ratios were 0.69 (0.48, 1.00; p = 0.05),
0.75 (0.59, 0.97; p = 0.03), 0.41 (0.20, 0.88; p = 0.02) and 1.49 (1.04, 2.14; p = 0.03). Genetically high iron
status was positively associated with liver cancer and inversely associated with brain cancer.
Keywords: iron; transferrin saturation; ferritin; serum transferrin; cancer; Mendelian randomization
1. Introduction
Hereditary hemochromatosis, an autosomal recessive disorder characterized by a progressive
iron overload, greatly increases the risk of developing hepatocellular carcinoma and non-neoplastic
liver diseases [1,2]. However, the carcinogenic effects of physiologically high levels of iron, an essential
nutrient influencing cell proliferation and growth [3], on liver cancer and non-hepatic malignancies
are unknown.
A randomized trial of 1277 individuals with peripheral arterial disease (636 in iron reduction
group through venesection and 641 in control group) found that in the iron reduction group, who
received regular phlebotomy, the risk of overall cancer, cancer-specific mortality and all-cause mortality
was lower than in the control group after 4.5 years of follow-up [4]. However, findings of observational
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studies are inconsistent or scarce concerning the effects of iron status on individual cancers, such as
colorectal, breast and oesophagal cancer [5–11]. Consequently, whether iron status (which is routinely
measured in clinical practice as serum iron, transferrin saturation, ferritin and transferrin) plays a role
in the development of site-specific cancer remains inconclusive.
Mendelian randomization (MR) is an approach that can strengthen the inference about the causal
nature of exposure–outcome associations by exploiting genetic variants as instrumental variables of
the exposures [12]. This method has the strength of minimizing confounding as genetic variants are
randomly assorted at conception, thereby being irrelevant to self-selected lifestyle and environmental
factors. Additionally, it overcomes reverse causality since allelic randomization antedates the disease’s
development. We conducted a two-sample MR study to systematically assess the possible causal
associations of four iron status biomarkers with risk of overall and 22 site-specific cancers.
2. Methods
2.1. Study Design Overview
We used a two-sample MR approach by using summary statistics data from a genome-wide
association study (GWAS) of iron status, the Breast Cancer Association Consortium and the UK Biobank,
which obtained appropriate patient consent and ethical approval. Overall cancer was treated as the
primary outcome and the site-specific cancers as secondary outcomes. Information on the studies and
consortia used in the present study is summarized in Supplementary Table S1. The present study was
approved by the Swedish Ethical Review Authority.
2.2. Instrumental Variable Selection
In a GWAS consisting of 48,972 individuals of European ancestry, the Genetics of Iron Status
Consortium identified five single nucleotide polymorphisms (SNP) associated with serum iron and
transferrin saturation, six SNPs associated with ferritin and eight SNPs associated with transferrin at
the genome-wide significance threshold (p < 5 × 10−8) [13] (Table 1). Among those SNPs, three SNPs
(rs1800562 and rs1799945 in HFE and rs855791 in TMPRSS6) showed a robust and consistent association
with a systemic iron status and explained the majority of variance for each iron status biomarker [14]
and have been used as instrumental variables for iron status in previous MR studies [14–16]. The SNPs
were uncorrelated (R2 < 0.01) and explained 3.4%, 7.2%, 6.9% and 0.9% of the variance for serum iron,
transferrin, transferrin saturation and ferritin levels, respectively [13]. Details of the SNPs associated
with the iron status biomarkers are presented in Table 1.
2.3. Outcome Data Sources
Summary-level data for breast cancer (including estrogen receptor positive and negative breast
cancer) were obtained from the Breast Cancer Association Consortium with 228,951 individuals of
European ancestry (122,977 cancer cases and 105,974 controls) [17]. The GWAS for breast cancer used
1000 Genomes Project (Phase 3) reference panel in imputation stage and the logistic regression analyses
adjusted for genetic principal components and country.
Summary-level data for overall cancer and 22 site-specific cancers were extracted from the UK
Biobank [18]. This cohort study recruited around 500,000 adults, aged 40 to 69 years, across the
UK from 2006 to 2010. To reduce population stratification bias, we confided the study population
to European-descent individuals. After exclusion of related individuals (third-degree relatives or
closer), low call rate, and excess heterozygosity (3 or more standard deviations from the mean), 367,643
participants remained in the analyses and were followed up until March 31, 2017, or death. In total,
there were 75,037 cancer cases at any site.
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Table 1. SNPs associated with iron status biomarkers at genome-wide significance level and included in the main analyses with three primary SNPs and secondary
analyses of all SNPs.
SNP Nearby
Gene
EA EAF
Serum Iron, µmol/L Transferrin Saturation, % Log10 Ferritin, µg/L Ferritin, g/L
Beta SE p Beta SE p Beta SE p Beta SE p
rs1800562 * HFE A 0.07 0.328 0.016 2.9 × 10−97 0.577 0.016 2.2 × 10−270 0.204 0.016 1.5 × 10−38 −0.479 0.016 8.9 × 10−196
rs1799945 * HFE G 0.15 0.189 0.010 1.1 × 10−81 0.231 0.010 5.1 × 10−109 0.065 0.010 1.7 × 10−10 −0.114 0.010 9.4 × 10−30
rs855791 * TMPRSS6 G 0.55 0.181 0.007 4.3 × 10−139 0.190 0.007 6.4 × 10−137 0.055 0.007 1.4 × 10−14 −0.044 0.007 2.0 × 10−9
rs8177240 TF G 0.35 0.066 0.007 6.6 × 10−20 0.100 0.008 7.2 × 10−38 0.380 0.007 8.4 × 10−610
rs7385804 TFR2 A 0.62 0.064 0.007 1.4 × 10−18 0.054 0.008 6.1 × 10−12
rs744653 AC013439.4 C 0.16 0.089 0.010 8.4 × 10−19
rs411988 TEX14 G 0.44 0.044 0.007 1.6 × 10−10
rs651007 ABO C 0.79 0.050 0.009 1.3 × 10−8
rs4921915 NAT2 A 0.76 0.079 0.009 7.1 × 10−19
rs174577 FADS2 A 0.36 0.062 0.007 2.3 × 10−17
rs9990333 TFRC C 0.53 0.051 0.007 2.0 × 10−13
rs6486121 ARNTL C 0.34 0.046 0.007 3.9 × 10−10
EA indicates effect allele; EAF, effect allele frequency; SE, standard error; SNP, single nucleotide polymorphism. * Three SNPs were included in the main analyses.
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2.4. Statistical Analysis
The inverse-variance weighted method with random-effects was used to assess the causal
associations between iron status and cancer risk. In the main analysis, we employed three genetic
variants (rs1800562 and rs1799945 in HFE and rs855791 in TMPRSS6), explaining the major proportion
of variance for iron status, as instrumental variables. All SNPs reaching the genome-wide significance
level for individual iron status indicators were used in the sensitivity analysis. Furthermore, we
performed sensitivity analyses, including the weighted median [19] and MR-Egger methods [20], for
associations with p < 0.05 in the inverse-variance weighted models. Odds ratios (ORs) of cancer are
per one standard deviation (SD) increase in genetically predicted serum iron, log10 ferritin, ferritin
saturation and transferrin levels in all analyses. Power calculations were based on a method designed
for a binary outcome [21]; results from these analyses are displayed in Supplementary Figure S1. All
statistical analyses were two-sided and performed in Stata/SE 15.0 and R 3.6.0 software. We searched
the PhenoScanner V2 database [22] (a database of human genotype-phenotype associations) to detect
possible pleiotropy for the SNPs associated with the iron status biomarkers. The p values were not
strictly used to define statistical significance, but we interpreted the results based on the strengths of
the associations [23] as well as the consistency across sensitivity analyses.
3. Results
Genetically predicted high iron status was positively associated with liver cancer and inversely
associated with brain cancer but was not associated with overall cancer and the other 20 cancers
(Table 2). The OR of liver cancer was 2.45 (95% CI, 0.81, 7.45; p = 0.11), 2.11 (95% CI, 1.16, 3.83; p = 0.02),
10.89 (95% CI, 2.44, 48.59; p = 0.002) and 0.30 (95% CI, 0.17, 0.53; p = 2 × 10−5) for one SD increase
in genetically predicted serum iron, log10 ferritin, ferritin saturation and transferrin levels. Results
were consistent across sensitivity analyses (Table 3). Substantial heterogeneity among estimates of
individual SNPs (I2 = 76, p = 0.01) and potential pleiotropy (intercept −0.662 (95% CI -1.124, -0.199);
p = 5.00 × 10−3) were detected in the analysis of serum iron levels. The associations of iron status
biomarkers with liver cancer were mainly driven by rs1800562 in HFE (Table 3), which had the largest
effect on iron status (Table 1). Even though none of the associations remained significant, the magnitude
and direction of associations were similar after excluding that SNP (Supplementary Table S2). The OR
of brain cancer was 0.69 (95% CI, 0.48, 1.00; p = 0.05), 0.75 (95% CI, 0.59, 0.97; p = 0.03), 0.41 (95%
CI, 0.20, 0.88; p = 0.02) and 1.49 (95% CI, 1.04, 2.14; p = 0.03) per one SD increment of serum iron,
log10 ferritin, ferritin saturation and transferrin levels. The results for brain cancer were consistent
and robust in all sensitivity analyses, and no heterogeneity and pleiotropy was observed (Table 4).
However, as for liver cancer, the associations did not remain after removing rs1800562 (Supplementary
Table S2).
Nutrients 2020, 12, 526 5 of 12
Table 2. Associations between genetically predicted iron status, based on three primary SNPs, and overall cancer and 22 site-specific cancers.
Cancer Cases
Serum Iron Transferrin Saturation Ferritin Transferrin
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Overall cancer (UKBB) 75,037 1.03 (0.96, 1.10) 0.47 1.01 (0.96, 1.07) 0.65 1.03 (0.88, 1.21) 0.71 1.00 (0.92, 1.08) 0.99
Brain and head and neck
Brain 810 0.69 (0.48, 1.00) 0.05 0.75 (0.59, 0.97) 0.03 0.41 (0.20, 0.88) 0.02 1.49 (1.04, 2.14) 0.03
Head and neck 1615 0.93 (0.71, 1.23) 0.63 0.97 (0.79, 1.19) 0.77 0.93 (0.50, 1.72) 0.81 0.99 (0.73, 1.34) 0.95
Gastrointestinal tract
Oesophagus 843 0.95 (0.68, 1.33) 0.76 0.95 (0.75, 1.20) 0.66 0.82 (0.40, 1.71) 0.60 1.11 (0.78, 1.57) 0.56
Stomach 736 1.11 (0.67, 1.83) 0.70 1.00 (0.75, 1.35) 0.97 1.00 (0.41, 2.46) 0.99 1.06 (0.69, 1.61) 0.80
Colorectum 5486 0.99 (0.70, 1.41) 0.95 0.98 (0.76, 1.26) 0.89 0.95 (0.44, 2.04) 0.90 1.06 (0.74, 1.51) 0.76
Pancreas 1264 1.03 (0.72, 1.48) 0.86 1.04 (0.81, 1.34) 0.76 1.17 (0.55, 2.52) 0.68 0.92 (0.64, 1.32) 0.65
Liver 324 2.45 (0.81, 7.45) 0.11 2.11 (1.16, 3.83) 0.01 10.89 (2.44, 48.59) 2.0 × 10−3 0.30 (0.17, 0.53) 2.0 × 10−5
Biliary tract 387 0.67 (0.34, 1.32) 0.25 1.06 (0.65, 1.72) 0.81 1.33 (0.31, 5.63) 0.70 0.77 (0.42, 1.43) 0.41
Sex-specific
Breast (UKBB) 13,666 1.10 (1.00, 1.22) 0.05 1.06 (0.98, 1.16) 0.16 1.18 (0.89, 1.56) 0.25 0.94 (0.81, 1.10) 0.47
Breast (BCAC) 122,977 0.99 (0.94, 1.03) 0.62 0.99 (0.96, 1.03) 0.65 0.98 (0.88, 1.08) 0.66 1.01 (0.96, 1.06) 0.75
Breast ER+ (BCAC) 69,501 1.01 (0.96, 1.07) 0.73 1.00 (0.97, 1.03) 0.85 1.03 (0.91, 1.17) 0.63 0.98 (0.93, 1.05) 0.60
Breast ER- (BCAC) 21,468 0.93 (0.85, 1.01) 0.07 0.95 (0.89, 1.01) 0.08 0.85 (0.70, 1.02) 0.09 1.07 (0.98, 1.18) 0.14
Uterus 1931 0.99 (0.79, 1.24) 0.95 0.98 (0.84, 1.15) 0.83 0.94 (0.58, 1.53) 0.80 1.06 (0.83, 1.33) 0.65
Cervix 1928 1.11 (0.88, 1.41) 0.38 1.06 (0.88, 1.27) 0.53 1.18 (0.67, 2.08) 0.57 0.97 (0.73, 1.30) 0.84
Ovary 1520 0.98 (0.69, 1.39) 0.91 0.97 (0.76, 1.24) 0.82 0.92 (0.43, 1.94) 0.82 1.08 (0.76, 1.53) 0.66
Prostate 7872 1.10 (0.91, 1.33) 0.34 1.07 (0.94, 1.22) 0.32 1.24 (0.83, 1.85) 0.29 0.91 (0.74, 1.12) 0.40
Testis 735 1.11 (0.77, 1.60) 0.57 1.11 (0.86, 1.44) 0.43 1.42 (0.64, 3.12) 0.39 0.81 (0.56, 1.19) 0.29
Urinary tract
Bladder 2588 1.08 (0.89, 1.31) 0.46 1.045 (0.91, 1.2) 0.51 1.15 (0.75, 1.76) 0.52 0.96 (0.78, 1.17) 0.67
Kidney 1310 0.97 (0.73, 1.28) 0.82 1.01 (0.82, 1.23) 0.95 1.07 (0.58, 1.96) 0.83 0.93 (0.70, 1.23) 0.60
Blood/bone marrow/lymph
Leukemia 1403 0.99 (0.77, 1.29) 0.96 0.98 (0.81, 1.18) 0.82 0.91 (0.51, 1.61) 0.75 1.07 (0.81, 1.40) 0.65
Non-Hodgkin lymphoma 2296 0.92 (0.75, 1.13) 0.43 0.95 (0.82, 1.10) 0.50 0.87 (0.55, 1.36) 0.53 1.05 (0.84, 1.30) 0.67
Multiple myeloma 656 0.80 (0.41, 1.59) 0.53 0.80 (0.60, 1.08) 0.15 0.51 (0.21, 1.22) 0.13 1.33 (0.82, 2.14) 0.25
Other
Thyroid 375 1.68 (0.63, 4.49) 0.30 1.54 (0.81, 2.93) 0.19 4.06 (0.65, 25.53) 0.14 0.51 (0.21, 1.24) 0.14
Lung 2838 0.93 (0.77, 1.12) 0.43 0.93 (0.82, 1.07) 0.31 0.80 (0.54, 1.20) 0.29 1.13 (0.94, 1.37) 0.20
Melanoma 4869 0.96 (0.83, 1.11) 0.58 0.98 (0.88, 1.08) 0.66 0.94 (0.69, 1.28) 0.71 1.01 (0.87, 1.18) 0.86
BCAC indicates Breast Cancer Association Consortium; CI; confidence interval; ER, estrogen receptor; OR, odds ratio; UKBB, UK Biobank. All estimations were based on the inverse-variance
weighted method with random-effects.
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Table 3. Associations between genetically predicted iron status, based on three primary SNPs, and liver cancer in sensitivity analyses.
SNP (Gene) or Method
Serum Iron Transferrin Saturation Ferritin Transferrin
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
rs1800562 (HFE) 6.65 (2.78, 15.9) 2.02 × 10−5 2.94 (1.79, 4.82) 2.02 × 10−5 21.0 (5.18, 85.4) 2.02 × 10−5 0.27 (0.15, 0.50) 2.02 × 10−5
rs1799945 (HFE) 1.01 (0.32, 3.16) 0.99 1.01 (0.40, 2.56) 0.99 1.03 (0.04, 28.3) 0.99 0.98 (0.15, 6.50) 0.99
rs855791 (TMPRSS6) 1.54 (0.65, 3.64) 0.32 1.51 (0.67, 3.42) 0.32 4.14 (0.24, 70.3) 0.32 0.17 (0.01, 5.82) 0.32
IVW-Random effects 2.45 (0.81, 7.45) 0.11 2.11 (1.16, 3.83) 0.01 10.9 (2.44, 48.6) 2.00 × 10−3 0.30 (0.17, 0.53) 2.99 × 10−5
Weighted median 2.08 (0.97, 4.47) 0.06 2.14 (1.39, 3.31) 1.00 × 10−3 12.1 (3.24, 45.2) 3.43 × 10−4 0.30 (0.17, 0.53) 3.31 × 10−5
MR-Egger 49.0 (5.64, 424) 4.17 × 10−4 4.36 (1.87, 10.1) 1.00 × 10−3 46.4 (5.47, 394) 4.38 × 10−4 0.28 (0.11, 0.70) 7.00 × 10−3
Heterogeneity (I2) 76 (23, 93) 0.01 58 (0, 88) 0.09 38 (0, 81) 0.20 0 (0, 90) 0.43
Pleiotropy (Intercept) NA 5.00 × 10−3 NA 0.06 NA 0.11 NA 0.76
CI indicates confidence interval; IVW, inverse-variance weighted; NA, Not Available; OR, odds ratio; SNP, single nucleotide polymorphism.
Table 4. Associations between genetically predicted iron status, based on 3 primary SNPs, and brain cancer in sensitivity analyses.
SNP (Gene) or Method
Serum Iron Transferrin Saturation Ferritin Transferrin
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
rs1800562 (HFE) 1.09 (0.53, 2.24) 0.82 1.07 (0.59, 1.93) 0.82 1.28 (0.16, 10.4) 0.82 5.04 (0.54, 47.4) 0.82
rs1799945 (HFE) 0.54 (0.31, 0.95) 0.16 0.69 (0.41, 1.16) 0.16 0.27 (0.05, 1.65) 0.16 0.87 (0.26, 2.88) 0.16
rs855791 (TMPRSS6) 0.67 (0.39, 1.16) 0.03 0.71 (0.51, 0.97) 0.03 0.37 (0.15, 0.92) 0.03 1.52 (1.04, 2.23) 0.03
IVW-Random effects 0.69 (0.48, 1.00) 0.05 0.75 (0.59, 0.97) 0.03 0.41 (0.20, 0.88) 0.02 1.49 (1.04, 2.14) 0.03
Weighted median 0.65 (0.44, 0.96) 0.03 0.71 (0.53, 0.93) 0.02 0.37 (0.16, 0.83) 0.02 1.46 (1.01, 2.13) 0.05
MR-Egger 0.35 (0.07, 1.63) 0.18 0.68 (0.36, 1.29) 0.24 0.36 (0.08, 1.69) 0.19 1.38 (0.74, 2.57) 0.31
Heterogeneity (I2) 11 (0, 91) 0.33 0 (0, 90) 0.44 0 (0, 90) 0.51 0 (0, 90) 0.38
Pleiotropy (Intercept) NA 0.37 NA 0.72 NA 0.82 NA 0.72
CI indicates confidence interval; IVW, inverse-variance weighted; NA, Not Available; OR, odds ratio; SNP, single nucleotide polymorphism.
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In the sensitivity analyses using all SNPs for each iron status biomarker, the direction and
magnitude of the effects of iron status on liver and brain cancer remained, but only the associations of
serum iron levels with brain cancer and of transferrin saturation with liver and brain cancer reached
the conventional level of significance (Supplementary Figures S2–S5). The associations did not remain
after removing rs1800562 (Supplementary Table S2).
The three SNPs used as instrumental variables for the main analysis were associated with blood
cells, HbA1c and blood pressure at genome-wide significance. Rs1800562 in HFE was additionally
related to some other traits, such as height, lipids and pulse rate (Supplementary Table S3). The other
SNPs included in the secondary analysis had pleiotropic associations with multiple traits, such as
blood cells, cardiovascular diseases, blood lipids, plasma fatty acids, interleukins, pulse rate, asthma
and heart rate.
4. Discussion
The present two-sample MR study is the first to systematically evaluate the causal role of iron
status for a wide range of cancers. It showed that genetically high iron status was associated with
higher risk of liver cancer and lower risk of brain cancer. These associations were driven by rs1800562,
which had the largest impact on iron status among the instrumental variables. There was no evidence
in support of a causal association of high iron status with overall cancer and 20 other cancers.
Our results are in line with abundant data from observational and experimental studies, indicating
carcinogenic effects of high iron levels on liver cancer. In a recent meta-analysis of cohort and
case-control studies, serum ferritin (6 studies) and serum iron (3 studies) levels in the highest category
were associated with 1.5- and 2.5-fold increases in risk of liver cancer, respectively, when compared to
levels in the lowest group [9]. Moreover, high transferrin saturation (≥60% versus <50%) was reported
to be associated with a significant 5.9-fold higher risk of liver cancer in a prospective cohort of 8763
Danish adults followed up for 15 years [24]. In addition, hepatocellular carcinoma risk is substantially
increased among individuals with hemochromatosis gene mutations and in hemochromatosis patients
diagnosed by elevated serum transferrin saturation and ferritin levels [1,25,26]. Notably, the two
HFE SNPs included in this study are known to cause forms of haemochromatosis, with rs1800562
(C282Y) causing a particularly serious type, and rs1799945 (H63D) causing a milder form [27,28]. These
SNPs are related to decreased levels of hepcidin, thereby causing the increase of iron absorption and
parenchymal deposition (iron overload) in the liver [29]. Our findings are therefore consistent with
previous reports that heterozygosity and combined heterozygosity of these two SNPs are associated
with liver cancer. A recent review indicated that iron overload was a common consequence of an
excessive and prolonged consumption of alcohol. An increased level of iron was observed in both
serum and within cells, hepatocytes in particular [30]. Furthermore, a dose-response relationship has
been observed between alcohol consumption and liver cancer [31]. In the present study, SNPs used for
iron status were not related to alcohol consumption, implying that the observed association between
iron status and liver cancer is unlikely driven by alcohol consumption. Thus, it is speculated that
elevated iron status may partly mediate the pathway from alcohol consumption to liver cancer, which
is in line with our findings indirectly.
These epidemiologic associations between iron status and liver cancer have been further supported
by animal studies. Long-Evans Cinnamon rats fed an iron-deficient diet for 65 weeks exhibit lower risk
of fulminant hepatitis, hepatic fibrosis, and subsequent hepatocarcinogenesis compared with those
fed a normal diet after a 65-week intervention [32]. Similarly, iron deposition in the liver is likely to
promote liver cancer in humans as patients with hepatocellular carcinoma complicating noncirrhotic
liver [33] and non-alcoholic steato-hepatitis [34] have higher iron deposition in non-tumorous areas of
the liver than those without cancer. A range of putative carcinomic mechanisms of high iron status in
the liver have been proposed, including deoxyribonucleic acid damage and cytotoxic by-products of
lipid peroxidation caused by reactive oxygen species, free radicals, ferroptosis [26,35,36], facilitation of
cancer growth [37], and lymphocyte and macrophage functions impairment [35].
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This MR study, therefore, adds strong causal evidence to previous observational and experimental
studies that high physiological levels of iron status promote liver cancer. This has important clinical
implications with regards to the treatment of borderline anaemia and the continuation of iron therapies
in anaemic patients after their iron status has been corrected, particularly if patients are asymptomatic.
Conversely, there may be a benefit to careful reduction of iron indices for reducing liver cancer risk in
patients with high physiological iron status or in patients who are at risk due to other factors such as
alcohol-related liver disease or viral hepatitis. Further studies should address the risk of liver cancer in
patients receiving long-term iron therapy with borderline anaemia or normalized iron status. Similarly,
the benefits of regular phlebotomy or iron chelation seen with hemochromatosis may potentially be
extended in specific groups of patients with high physiological iron levels.
Data on the association between iron status and brain cancer are limited. Nevertheless, iron-related
gene expression has been reported to be dysregulated in brain tumours, such as elevated HFE
expression in meningioma [38] an iron redox state affects brain cancer severity. These studies
suggest that iron homeostasis may be involved in the development of brain cancer, but more
broadly, several studies have shown that iron has important effects on the brain. Iron deficiency
causes neuropsychologic impairment [39] and behavioural dysfunction [40], and even contributed
to long-term organic change in brain, such as dopamine metabolism, myelination, and hippocampal
structure and function [40]. Additionally, it has been postulated that both iron excess and deficiency
lead to oxidative deoxyribonucleic acid damage, thereby increasing the risk of cancer [3]. Consistent
with a protective effect of low iron levels on brain cancer risk, iron chelation with deferoxamine
has been suggested as a novel approach to therapy for brain cancer, due to antiproliferative effects,
which are mediated by an intracellular pool of iron [37]. Genetic evidence also lends support to our
findings stating that the TMPRSS6 gene exerts an important role in the absorption of dietary iron
via intestines and transporting out iron from storage sites (particularly in the liver and spleen) to
other organs via the bloodstream [41]. Iron status in the brain can be different from other organs due
to the presence of the blood-brain barrier. It has been well acknowledged that iron is taken up by
means of receptor-mediated uptake of iron-transferrin at the blood-brain barrier, thereby transporting
iron from the circulation into the brain extracellular space [42]. Our study showed that both lower
serum iron and higher transferrin levels were associated with higher risk of brain cancer. An animal
study indicated that iron supplementation prevented lead-induced disruption of the blood–brain
barrier in the rat development [43]. Population-based studies have also found that iron deficiency
caused alternations of brain development and functioning, possibly also affecting the brain barrier [44].
Blood-brain barrier breakdown or alterations in transport systems have been shown to play a vital role
in the pathogenesis of many central nervous system diseases, including tumours [45]. Considering the
important role of the blood–brain barrier for iron homeostasis and tumours in the brain along with
limited and inconsistent findings of the effects of physiologically high iron levels on blood-brain barrier,
additional research on the effects of iron status on blood-brain barrier function and on brain cancer risk
is warranted. Although our MR study provides causal evidence of an inverse relationship between
iron status and overall brain cancer, considering the small number of brain cancer cases, additional
studies with larger sample sizes are warranted to verify our findings. Furthermore, the effects of iron
on brain cancer types need to be explored.
A consistent, albeit nonsignificant pattern of high iron status in a high risk of thyroid cancer
was observed in the present study. In a study with 102 metastatic thyroid cancer patients, serum
ferritin levels were higher in the thyroid cancer group than among primary hypothyroid patients [46].
In addition, a recent cell study found a new pathway of E4BP4/G9a/SOSTDC1/hepcidin linking cellular
iron dysfunction to thyroid cancer [47]. The potential role of iron status in the development of thyroid
cancer needs further investigation.
Findings of observational studies of the association of iron status with other cancers are conflicting
or limited [8,10], but particular attention has related to dietary iron intake and colorectal cancer.
A systematic review and meta-analysis found that heme iron intake was positively associated with
Nutrients 2020, 12, 526 9 of 12
risk of colorectal and colon cancer, whereas serum iron levels were inversely associated with these
cancers [8]. However, the inverse association with serum iron levels may be related to reverse causality
as iron deficiency is a common presentation of colon cancer patients [48]. A prospective cohort study of
35,121 US men found no association between frequent blood donations, which may reduce body iron
stores, and colorectal cancer incidence or mortality [49]. Our results are, therefore, in agreement with
previous observational evidence, which do not support an important role of iron stores in colorectal
carcinogenesis. The previously observed findings for heme iron, which is found in meat, poultry, and
seafood, may be related to a local adverse effect of heme iron in the colorectum, such as a promoting
effect on intestinal N-nitroso compound formation [50]. Another recent meta-analysis found that heme
iron intake (based on six studies) and serum iron levels (based on four studies), but no other iron status
biomarkers, were significantly positively associated with risk of breast cancer [10]. The present study
showed no evidence supporting a causal association between iron status and breast cancer risk. The
discrepancy in findings from this MR study and previous observational studies may be attributed to
residual confounding from other compounds in meat, unhealthy dietary patterns or other lifestyle
behaviours. No consistent association has been reported between iron status and other cancers, but
epidemiological data are scarce [8].
A major strength of this study is the MR study design, which minimizes the confounding and
reverse causality seen in observational studies. In addition, we systematically assessed the associations
between four individual iron status indicators and 22 cancers using summary-level data from large-scale
genetic consortia and cohorts. The studies only used data from European populations. This reduced
population stratification bias but confined the transferability of our findings to other populations.
A major limitation of this study is that the statistical power was low in several analyses due to a
small number of cases for most cancer sites. In addition, this MR study investigated the association
of iron status within the normal range with cancer risk. Therefore, our results cannot be used to
make inferences regarding the effect of abnormally high serum iron levels caused by, for example,
intravenous, long-term oral iron supplementation or hemochromatosis.
5. Conclusions
The present study showed that genetically predicted iron status was positively associated with risk
of liver cancer and inversely associated with risk of brain cancer but not associated with overall cancer
and a number of other site-specific cancers among European-descent individuals. These findings need
to be interpreted with caution in light of the influential effect of a single variant in the HFE gene and
the limited number of liver and brain cancer cases. Nevertheless, our results, along with observational
data, highlight the importance of further research on the impact of adjustment of iron levels within the
physiological range, through supplementation or chelation, on risk of these cancers types. In particular,
careful consideration may be needed with regards to ongoing supplementation in anaemic patients or
those at high risk of liver cancer.
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